Abstract | BACKGROUND: METHODS: Men, aged 40 years and above, newly diagnosed with prostate cancer were categorized into two risk groups, low-grade (Gleason score, 6 or 7 [3 + 4] and serum prostate-specific antigen [PSA], <20 ng/mL) and high-grade (Gleason score, ≥7 (4 + 3) and serum PSA, ≥20 ng/mL) prostate cancers. The limma R package was used to compare the expression of miRNAs in plasma between the two risk groups, adjusting for age. RESULTS: There were 66 men, aged 46-86 years, included: 40 men with low-grade and 26 men with high-grade prostate cancers. There were lower expressions of miR-28, miR-100, miR-942, and miR-28-3p, and higher expressions of miR-708, miR-1298, miR-886-3p, miR-374, miR-376c, miR-202, miR-128a, and miR-185 in high-grade compared to low-grade prostate cancer cases at biopsy, after adjusting for age (P < 0.05). These differences were no longer statistically significant after adjusting the P values for multiple comparisons. CONCLUSION: There was no circulating miRNA associated with high-grade prostate cancer at biopsy after adjusting for age and multiple comparisons. Nevertheless, relationships between these circulating miRNAs and high-grade prostate cancer were observed, which suggest them as promising prostate cancer biomarkers. Further investigation in a larger cohort may provide insight into their diagnostic potential for aggressive prostate cancer.
|
Authors | Alicia C McDonald, Manish Vira, Vonn Walter, Jing Shen, Jay D Raman, Martin G Sanda, Dattatraya Patil, Emanuela Taioli |
Journal | The Prostate
(Prostate)
Vol. 79
Issue 9
Pg. 961-968
(06 2019)
ISSN: 1097-0045 [Electronic] United States |
PMID | 30958910
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Copyright | © 2019 Wiley Periodicals, Inc. |
Chemical References |
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Circulating MicroRNA
(biosynthesis, blood, genetics)
- Cross-Sectional Studies
- Humans
- Male
- Middle Aged
- Neoplasm Grading
- Prostatic Neoplasms
(blood, genetics, pathology)
|